Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for Journey Medical (DERM) over the last 5 years, with Sep 2025 value amounting to -$1.4 million.

  • Journey Medical's Change in Accured Expenses fell 3883.33% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 28944.44%. This contributed to the annual value of -$2.9 million for FY2024, which is 404.05% down from last year.
  • Per Journey Medical's latest filing, its Change in Accured Expenses stood at -$1.4 million for Q3 2025, which was down 203.34% from -$449,000 recorded in Q2 2025.
  • In the past 5 years, Journey Medical's Change in Accured Expenses ranged from a high of $14.3 million in Q2 2021 and a low of -$10.5 million during Q3 2021.
  • For the 3-year period, Journey Medical's Change in Accured Expenses averaged around $164,727, with its median value being -$317,000 (2024).
  • Data for Journey Medical's Change in Accured Expenses shows a peak YoY increase of 1,862.15% (in 2025) and a maximum YoY decrease of 3,883.33% (in 2025) over the last 5 years.
  • Journey Medical's Change in Accured Expenses (Quarterly) stood at -$2.1 million in 2021, then surged by 175.89% to $1.6 million in 2022, then surged by 169.41% to $4.3 million in 2023, then plummeted by 67.23% to $1.4 million in 2024, then crashed by 3,883.33% to -$1.4 million in 2025.
  • Its Change in Accured Expenses was -$1.4 million in Q3 2025, compared to -$449,000 in Q2 2025 and $5.6 million in Q1 2025.